RN Mobile Menu

Search form


Amy Reyes

Amy Reyes

Amy Reyes is editor of Rheumatology Network.  She is an experienced journalist and science writer who has worked as a staff writer for Mayo Clinic, the University of Michigan and Duke University Medical Center, where she specialized in covering advances in basic and clinical science in a multitude of disciplines.

Posts by Author

Dr. Philip G. Conaghan, University of Leeds, EULAR 2017

EULAR 20017: Despite the use of biologic therapy, pain ranging from mild to severe is a persistent problem for psoriatic arthritis patients, researchers reported at EULAR 2017.

Karim Sacre, M.D., of Paris University, EULAR 2017

EULAR 2017: Although already known to be highly prevalent, this test reveals that cardiovascular events are even more widespread in lupus.

EULAR 2017 (Photo courtesy of EULAR_6282)

EULAR 2017 wraps on Saturday. In this slideshow, we highlight some of the most popular presentations from the meeting.

Bruno Fautrel, M.D., Ph.D, Pitié Salpêtrière University Hospital

EULAR 2017: Undifferentiated arthritis or very early rheumatoid arthritis should be treated soon after diagnosis to prevent advanced arthritis.

Dr. Piet Geusens, Maastricht University, The Netherlands

EULAR 2017: Romosozumab reduces the risk of clinical vertebral fractures in postmenopausal women with osteoporosis by as much as five times.

Arthritis (©Fineart1/Shutterstock.com)

Rheumatoid arthritis patients with lower MBDA scores respond better to triple therapy vs. methotrexate and infliximab combo.

Osteoporosis (©JavierRegueiro/Shutterstock.com)

For the first time in seven years, the ACR has new treatment recommendations for glucocorticoid-induced osteoporosis. In this slideshow, we highlight the new guidelines.


The severity of long-term chronic pain that impedes daily life seems to be associated with higher mortality, researchers report.


Sjogren’s fails a clinical trial with rituximab and a cost analysis. Even with a significant discount, it’s still not cost effective.


The biosimilar adalimumab-atto is equivalent to its reference product — which it slightly outperformed in this trial.


By clicking Accept, you agree to become a member of the UBM Medica Community.